新股暗盤 | 騰盛博藥-B(2137.HK)暗盤段漲4%
格隆匯7月12日丨據富途證券,騰盛博藥-B(2137.HK)暗盤段現報23.15港元,較發行價22.25港元漲4.04%,成交量168.05萬手。公司是一家生物技術公司,致力於推進重大傳染病及其他具有重大公共衞生負擔疾病的療法。此次上市全球發售1.1158億股,其中香港發售5579萬股,國際發售5579萬股,每手500股,一手中籤率5%,香港公開發售獲292倍認購,淨籌23.338億港元,當中約55%劃撥至乙型肝炎病毒(HBV)功能性治癒項目的進一步發展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.